Status and phase
Conditions
Treatments
About
This is an open-label, single arm, multi-center Phase 2 study of oral Rocbrutinib in patients with mantle cell lymphoma who are failed or relapsed after remission or intolerated to Bruton's tyrosine kinase (BTK) inhibitor.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
62 participants in 1 patient group
Loading...
Central trial contact
Jun Zhu, MD, PhD; Yuqin Song, MD, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal